Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization

NCT: NCT07313800 · NOT_YET_RECRUITING

NCT IDNCT07313800
StatusNOT_YET_RECRUITING
Start Date2028-03-01
Completion2032-03-01
SponsorCortex Neurovascular (INDUSTRY)
First posted
Last updated

Brief Summary

This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1).

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑